Abstract:Background: Heart failure, which is a major global health problem, is often preceded by pathological cardiac hypertrophy. The expansion of the cardiac vasculature, to maintain adequate supply of oxygen and nutrients, is a key determinant of whether the heart grows in a physiological compensated manner or a pathological decompensated manner. Bidirectional endothelial cell (EC)-cardiomyocyte (CMC) cross talk via cardiokine and angiocrine signaling plays an essential role in the regulation of cardiac growth and homeostasis. Currently, the mechanisms involved in the EC-CMC interaction are not fully understood, and very little is known about the EC-derived signals involved. Understanding how an excess of angiogenesis induces cardiac hypertrophy and how ECs regulate CMC homeostasis could provide novel therapeutic targets for heart failure. Methods: Genetic mouse models were used to delete vascular endothelial growth factor (VEGF) receptors, adeno-associated viral vectors to transduce the myocardium, and pharmacological inhibitors to block VEGF and ErbB signaling in vivo. Cell culture experiments were used for mechanistic studies, and quantitative polymerase chain reaction, microarrays, ELISA, and immunohistochemistry were used to analyze the cardiac phenotypes. Results: Both EC deletion of VEGF receptor (VEGFR)-1 and adeno-associated viral vector-mediated delivery of the VEGFR1-specific ligands VEGF-B or placental growth factor into the myocardium increased the coronary vasculature and induced CMC hypertrophy in adult mice. The resulting cardiac hypertrophy was physiological, as indicated by preserved cardiac function and exercise capacity and lack of pathological gene activation. These changes were mediated by increased VEGF signaling via endothelial VEGFR2, because the effects of VEGF-B and placental growth factor on both angiogenesis and CMC growth were fully inhibited by treatment with antibodies blocking VEGFR2 or by endothelial deletion of VEGFR2. To identify activated pathways downstream of VEGFR2, whole-genome transcriptomics and secretome analyses were performed, and the Notch and ErbB pathways were shown to be involved in transducing signals for EC-CMC cross talk in response to angiogenesis. Pharmacological or genetic blocking of ErbB signaling also inhibited part of the VEGF-B-induced effects in the heart. Conclusions: This study reveals that cross talk between the EC VEGFR2 and CMC ErbB signaling pathways coordinates CMC hypertrophy with angiogenesis, contributing to physiological cardiac growth.

Reevaluation of the Role of Vegf-B Suggests A Restricted Role in the Revascularization of the Ischemic Myocardium

VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration

VEGFR endocytosis regulates the angiogenesis in a mouse model of hindlimb ischemia

Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

Contribution of VEGF-B-Induced Endocardial Endothelial Cell Lineage in Physiological Versus Pathological Cardiac Hypertrophy

Reversal of Angiogenic Growth Factor Upregulation by Revascularization of Lower Limb Ischemia

VEGF-B Selectively Regenerates Injured Peripheral Neurons and Restores Sensory and Trophic Functions

Complicated Life, Complicated VEGF-B.

VEGF-B is a potent antioxidant

Inhibiting Anti-angiogenic VEGF165b Activates a Novel miR-17-20a-Calcipressin-3 Pathway that Revascularizes Ischemic Muscle in Peripheral Artery Disease

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

Inhibiting anti-angiogenic VEGF165b activates a miR-17-20a-Calcipressin-3 pathway that revascularizes ischemic muscle in peripheral artery disease

Vascular Regeneration in Ischemic Hindlimb by Adeno‐Associated Virus Expressing Conditionally Silenced Vascular Endothelial Growth Factor

The biology of VEGF and its receptors

Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling

VEGF in biological control

Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.

Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium.

Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)